Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Liver Diseases

  Free Subscription


Articles published in Dig Dis

Retrieve available abstracts of 82 articles:
HTML format
Text format



Single Articles


    November 2017
  1. SHI L, Zhang X, Li J, Bai X, et al
    Favorable Effects of Endoscopic Ligation Combined with Drugs on Rebleeding and Mortality in Cirrhotic Patients: A Network Meta-Analysis.
    Dig Dis. 2017 Nov 21. doi: 10.1159/000484082.
    PubMed     Text format     Abstract available


    October 2017
  2. DYWICKI J, Noyan F, Misslitz AC, Hapke M, et al
    Hepatic T Cell Tolerance Induction in An Inflammatory Environment.
    Dig Dis. 2017 Oct 12. doi: 10.1159/000481341.
    PubMed     Text format     Abstract available


    July 2017
  3. XIAO W, Zheng J, Zhou B, Pan L, et al
    Replication Protein A 3 Is Associated with Hepatocellular Carcinoma Tumorigenesis and Poor Patient Survival.
    Dig Dis. 2017 Jul 7. doi: 10.1159/000478977.
    PubMed     Text format     Abstract available


  4. LABENZ C, Prenosil V, Koch S, Huber Y, et al
    Impact of Individual Components of the Metabolic Syndrome on the Outcome of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.
    Dig Dis. 2017 Jul 4. doi: 10.1159/000477578.
    PubMed     Text format     Abstract available


    March 2017
  5. DI PASCOLI M, Ceranto E, De Nardi P, Donato D, et al
    Hospitalizations Due to Cirrhosis: Clinical Aspects in a Large Cohort of Italian Patients and Cost Analysis Report.
    Dig Dis. 2017 Mar 1. doi: 10.1159/000458722.
    PubMed     Text format     Abstract available


    January 2017
  6. KEPPLER D
    Progress in the Molecular Characterization of Hepatobiliary Transporters.
    Dig Dis. 2017;35:197-202.
    PubMed     Text format     Abstract available


  7. HAUSSINGER D, Kordes C
    Mechanisms of Tauroursodeoxycholate-Mediated Hepatoprotection.
    Dig Dis. 2017;35:224-231.
    PubMed     Text format     Abstract available


  8. ALVAREZ-SOLA G, Uriarte I, Latasa MU, Urtasun R, et al
    Fibroblast Growth Factor 15/19 in Hepatocarcinogenesis.
    Dig Dis. 2017;35:158-165.
    PubMed     Text format     Abstract available


  9. PERUGORRIA MJ, Labiano I, Esparza-Baquer A, Marzioni M, et al
    Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment.
    Dig Dis. 2017;35:275-281.
    PubMed     Text format     Abstract available


  10. LARUSSO NF, Tabibian JH, O'Hara SP
    Role of the Intestinal Microbiome in Cholestatic Liver Disease.
    Dig Dis. 2017;35:166-168.
    PubMed     Text format     Abstract available


  11. REICH M, Klindt C, Deutschmann K, Spomer L, et al
    Role of the G Protein-Coupled Bile Acid Receptor TGR5 in Liver Damage.
    Dig Dis. 2017;35:235-240.
    PubMed     Text format     Abstract available


  12. HEGADE VS, Jones DE, Hirschfield GM
    Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.
    Dig Dis. 2017;35:267-274.
    PubMed     Text format     Abstract available


  13. STEINACHER D, Claudel T, Trauner M
    Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease.
    Dig Dis. 2017;35:282-287.
    PubMed     Text format     Abstract available


  14. HALILBASIC E, Steinacher D, Trauner M
    Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases.
    Dig Dis. 2017;35:288-292.
    PubMed     Text format     Abstract available


  15. PALLEN MJ, Quraishi MN
    The Gut Microbiota and the Hepatologist: Will Our Bugs Prove to be the Missing Link?
    Dig Dis. 2017;35:377-383.
    PubMed     Text format     Abstract available


  16. GALLE PR
    Treating Hepatobiliary Cancers: The Oncology Way.
    Dig Dis. 2017;35:384-386.
    PubMed     Text format     Abstract available


  17. POSE E, Cardenas A
    Translating Our Current Understanding of Ascites Management into New Therapies for Patients with Cirrhosis and Fluid Retention.
    Dig Dis. 2017;35:402-410.
    PubMed     Text format     Abstract available


  18. DUFFY AG, Greten TF
    Treating Hepatobiliary Cancer: The Immunologic Approach.
    Dig Dis. 2017;35:390-396.
    PubMed     Text format     Abstract available


  19. NEVENS F
    Novel Approaches to Reducing the Risk of Variceal Hemorrhage.
    Dig Dis. 2017;35:397-401.
    PubMed     Text format     Abstract available


  20. ROWE IA
    Lessons from Epidemiology: The Burden of Liver Disease.
    Dig Dis. 2017;35:304-309.
    PubMed     Text format     Abstract available


  21. TOWNSEND SA, Newsome PN
    The Role of a Dedicated Non-Alcoholic Fatty Liver Disease Clinic in 2016.
    Dig Dis. 2017;35:371-376.
    PubMed     Text format     Abstract available


  22. CHUNG BK, Karlsen TH
    Genetic Discoveries Highlight Environmental Factors as Key Drivers of Liver Disease.
    Dig Dis. 2017;35:323-333.
    PubMed     Text format     Abstract available


  23. WONG LL, Hegade VS, Jones DEJ
    What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?
    Dig Dis. 2017;35:359-366.
    PubMed     Text format     Abstract available


  24. THORGEIRSSON SS
    Stemness in Liver Cancer.
    Dig Dis. 2017;35:387-389.
    PubMed     Text format     Abstract available


  25. BAWDEN SJ, Scott RA, Aithal GP
    Current and Future Magnetic Resonance Technologies for Assessing Liver Disease in Clinical and Experimental Medicine.
    Dig Dis. 2017;35:314-322.
    PubMed     Text format     Abstract available


  26. IREDALE JP, Pellicoro A, Fallowfield JA
    Liver Fibrosis: Understanding the Dynamics of Bidirectional Wound Repair to Inform the Design of Markers and Therapies.
    Dig Dis. 2017;35:310-313.
    PubMed     Text format     Abstract available


  27. HIRAOKA A, Kumada T, Kudo M, Hirooka M, et al
    Hepatic Function during Repeated TACE Procedures and Prognosis after Introducing Sorafenib in Patients with Unresectable Hepatocellular Carcinoma: Multicenter Analysis.
    Dig Dis. 2017;35:602-610.
    PubMed     Text format     Abstract available


  28. NISHIDA N, Kudo M
    Role of Immune Checkpoint Blockade in the Treatment for Human Hepatocellular Carcinoma.
    Dig Dis. 2017;35:618-622.
    PubMed     Text format     Abstract available


  29. UESHIMA K, Nishida N, Kudo M
    Sorafenib-Regorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: A Single-Institute Experience.
    Dig Dis. 2017;35:611-617.
    PubMed     Text format     Abstract available


  30. ISHIKAWA T, Imai M, Owaki T, Sato H, et al
    Hemodynamic Changes on Cone-Beam Computed Tomography during Balloon-Occluded Transcatheter Arterial Chemoembolization Using Miriplatin for Hepatocellular Carcinoma: A Preliminary Study.
    Dig Dis. 2017;35:598-601.
    PubMed     Text format     Abstract available


  31. ARIZUMI T, Minami T, Chishina H, Kono M, et al
    Time to Transcatheter Arterial Chemoembolization Refractoriness in Patients with Hepatocellular Carcinoma in Kinki Criteria Stages B1 and B2.
    Dig Dis. 2017;35:589-597.
    PubMed     Text format     Abstract available


  32. ARIZUMI T, Minami T, Chishina H, Kono M, et al
    Impact of Tumor Factors on Survival in Patients with Hepatocellular Carcinoma Classified Based on Kinki Criteria Stage B2.
    Dig Dis. 2017;35:583-588.
    PubMed     Text format     Abstract available


  33. IWAMOTO T, Imai Y, Igura T, Kogita S, et al
    Non-Hypervascular Hypointense Hepatic Nodules during the Hepatobiliary Phase of Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced MRI as a Risk Factor of Intrahepatic Distant Recurrence after Radiofrequency Ablation of Hepatocellula
    Dig Dis. 2017;35:574-582.
    PubMed     Text format     Abstract available


  34. IDA H, Hagiwara S, Kono M, Minami T, et al
    Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.
    Dig Dis. 2017;35:565-573.
    PubMed     Text format     Abstract available


  35. UMEHARA Y, Hagiwara S, Nishida N, Sakurai T, et al
    Hepatocarcinogenesis Is Associated with Serum Albumin Levels after Sustained Virological Responses with Interferon-Based Therapy in Patients with Hepatitis C.
    Dig Dis. 2017;35:548-555.
    PubMed     Text format     Abstract available


  36. KOBAYASHI N, Kumada T, Toyoda H, Tada T, et al
    Ability of Cytokeratin-18 Fragments and FIB-4 Index to Diagnose Overall and Mild Fibrosis Nonalcoholic Steatohepatitis in Japanese Nonalcoholic Fatty Liver Disease Patients.
    Dig Dis. 2017;35:521-530.
    PubMed     Text format     Abstract available


  37. KITAHATA S, Hiraoka A, Kudo M, Murakami T, et al
    Abdominal Ultrasound Findings of Tumor-Forming Hepatic Malignant Lymphoma.
    Dig Dis. 2017;35:498-505.
    PubMed     Text format     Abstract available


    June 2016
  38. FITZ JG
    Hepatology after Hepatitis C.
    Dig Dis. 2016;34:603-606.
    PubMed     Text format     Abstract available


  39. DIAZ-GONZALEZ A, Reig M, Bruix J
    Treatment of Hepatocellular Carcinoma.
    Dig Dis. 2016;34:597-602.
    PubMed     Text format     Abstract available


  40. HALILBASIC E, Fuchs C, Traussnigg S, Trauner M, et al
    Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease.
    Dig Dis. 2016;34:580-588.
    PubMed     Text format     Abstract available


    January 2016
  41. HOGDALL D, O'Rourke CJ, Taranta A, Oliveira DV, et al
    Molecular Pathogenesis and Current Therapy in Intrahepatic Cholangiocarcinoma.
    Dig Dis. 2016;34:440-51.
    PubMed     Text format     Abstract available


  42. SCHMIDT N, Thimme R
    Role of Immunity in Pathogenesis and Treatment of Hepatocellular Carcinoma.
    Dig Dis. 2016;34:429-37.
    PubMed     Text format     Abstract available


  43. GERBES AL
    Liver Cirrhosis and Kidney.
    Dig Dis. 2016;34:387-90.
    PubMed     Text format     Abstract available


  44. GARCIA-TSAO G
    Current Management of the Complications of Cirrhosis and Portal Hypertension: Variceal Hemorrhage, Ascites, and Spontaneous Bacterial Peritonitis.
    Dig Dis. 2016;34:382-6.
    PubMed     Text format     Abstract available


  45. SAFFIOTI F, Pinzani M
    Development and Regression of Cirrhosis.
    Dig Dis. 2016;34:374-81.
    PubMed     Text format     Abstract available


  46. ZOLLER H, Henninger B
    Pathogenesis, Diagnosis and Treatment of Hemochromatosis.
    Dig Dis. 2016;34:364-73.
    PubMed     Text format     Abstract available


  47. JAHN D, Rau M, Wohlfahrt J, Hermanns HM, et al
    Non-Alcoholic Steatohepatitis: From Pathophysiology to Novel Therapies.
    Dig Dis. 2016;34:356-63.
    PubMed     Text format     Abstract available


  48. THIMME R
    Highlights from Hepatology 2015: From Chronic Hepatitis to Hepatocellular Carcinoma.
    Dig Dis. 2016;34:I-II.
    PubMed     Text format    


  49. KUDO M
    Recent Trends in the Management of Hepatocellular Carcinoma with Special Emphasis on Treatment with Regorafenib and Immune Checkpoint Inhibitors.
    Dig Dis. 2016;34:714-730.
    PubMed     Text format     Abstract available


  50. NISHIDA N, Kudo M
    Clinical Significance of Epigenetic Alterations in Human Hepatocellular Carcinoma and Its Association with Genetic Mutations.
    Dig Dis. 2016;34:708-713.
    PubMed     Text format     Abstract available


  51. NAGAI T, Arao T, Nishio K, Matsumoto K, et al
    Impact of Tight Junction Protein ZO-1 and TWIST Expression on Postoperative Survival of Patients with Hepatocellular Carcinoma.
    Dig Dis. 2016;34:702-707.
    PubMed     Text format     Abstract available


  52. OGAWA C, Minami Y, Morita M, Noda T, et al
    Prediction of Embolization Area after Conventional Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Using SYNAPSE VINCENT.
    Dig Dis. 2016;34:696-701.
    PubMed     Text format     Abstract available


  53. KAWASAKI T, Hata KY, Kinoshita D, Takayama M, et al
    Radiofrequency Ablation Guided by Contrast-Enhanced Sonography versus B-Mode Sonography for Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization.
    Dig Dis. 2016;34:692-695.
    PubMed     Text format     Abstract available


  54. IWAMOTO T, Imai Y, Kogita S, Igura T, et al
    Comparison of Contrast-Enhanced Ultrasound and Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-Enhanced MRI for the Diagnosis of Macroscopic Type of Hepatocellular Carcinoma.
    Dig Dis. 2016;34:679-686.
    PubMed     Text format     Abstract available


  55. ARIZUMI T, Ueshima K, Iwanishi M, Minami T, et al
    Validation of Kinki Criteria, a Modified Substaging System, in Patients with Intermediate Stage Hepatocellular Carcinoma.
    Dig Dis. 2016;34:671-678.
    PubMed     Text format     Abstract available


  56. CHISHINA H, Hagiwara S, Nishida N, Ueshima K, et al
    Clinical Factors Predicting the Effect of Tolvaptan for Refractory Ascites in Patients with Decompensated Liver Cirrhosis.
    Dig Dis. 2016;34:659-664.
    PubMed     Text format     Abstract available


  57. YADA N, Sakurai T, Minami T, Arizumi T, et al
    Prospective Risk Analysis of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C by Ultrasound Strain Elastography.
    Dig Dis. 2016;34:650-653.
    PubMed     Text format     Abstract available


  58. SCORLETTI E, Byrne CD
    Extrahepatic Diseases and NAFLD: The Triangular Relationship between NAFLD, Type 2-Diabetes and Dysbiosis.
    Dig Dis. 2016;34 Suppl 1:11-8.
    PubMed     Text format     Abstract available


  59. MAZZOTTI A, Caletti MT, Sasdelli AS, Brodosi L, et al
    Pathophysiology of Nonalcoholic Fatty Liver Disease: Lifestyle-Gut-Gene Interaction.
    Dig Dis. 2016;34 Suppl 1:3-10.
    PubMed     Text format     Abstract available


  60. MAHLI A, Hellerbrand C
    Alcohol and Obesity: A Dangerous Association for Fatty Liver Disease.
    Dig Dis. 2016;34 Suppl 1:32-9.
    PubMed     Text format     Abstract available


  61. SCHERER A, Dufour JF
    Treatment of Non-Alcoholic Fatty Liver Disease.
    Dig Dis. 2016;34 Suppl 1:27-31.
    PubMed     Text format     Abstract available


  62. DE ALWIS NM, Anstee QM, Day CP
    How to Diagnose Nonalcoholic Fatty Liver Disease.
    Dig Dis. 2016;34 Suppl 1:19-26.
    PubMed     Text format     Abstract available


  63. MINAMI Y, Minami T, Chishina H, Kono M, et al
    US-US Fusion Imaging in Radiofrequency Ablation for Liver Metastases.
    Dig Dis. 2016;34:687-691.
    PubMed     Text format     Abstract available


  64. TAKITA M, Iwanishi M, Minami T, Kono M, et al
    Monoethanolamine Oleate Sclerotherapy for Polycystic Liver Disease.
    Dig Dis. 2016;34:654-658.
    PubMed     Text format     Abstract available


  65. GALLE PR
    Extended Abstract: Management of Liver Cancer.
    Dig Dis. 2016;34:438-9.
    PubMed     Text format     Abstract available


  66. WEISKIRCHEN R, Tacke F
    Liver Fibrosis: From Pathogenesis to Novel Therapies.
    Dig Dis. 2016;34:410-22.
    PubMed     Text format     Abstract available


  67. LAMMERT F
    Genetics in Common Liver Diseases: From Pathophysiology to Precise Treatment.
    Dig Dis. 2016;34:391-5.
    PubMed     Text format     Abstract available


  68. CHAZOUILLERES O
    Novel Aspects in the Management of Cholestatic Liver Diseases.
    Dig Dis. 2016;34:340-6.
    PubMed     Text format     Abstract available


  69. KOYAMA Y, Xu J, Liu X, Brenner DA, et al
    New Developments on the Treatment of Liver Fibrosis.
    Dig Dis. 2016;34:589-96.
    PubMed     Text format     Abstract available


    January 2015
  70. PARES A
    Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid.
    Dig Dis. 2015;33 Suppl 2:125-33.
    PubMed     Text format     Abstract available


  71. HERKEL J
    Regulatory T Cells in Hepatic Immune Tolerance and Autoimmune Liver Diseases.
    Dig Dis. 2015;33 Suppl 2:70-4.
    PubMed     Text format     Abstract available


  72. JOPSON L, Jones DE
    Fatigue in Primary Biliary Cirrhosis: Prevalence, Pathogenesis and Management.
    Dig Dis. 2015;33 Suppl 2:109-14.
    PubMed     Text format     Abstract available


  73. CORRIGAN M, Hirschfield GM
    Aspects of the Pathophysiology of Primary Biliary Cirrhosis.
    Dig Dis. 2015;33 Suppl 2:102-8.
    PubMed     Text format     Abstract available


  74. KOHLI R, Myronovych A, Tan BK, Salazar-Gonzalez RM, et al
    Bile Acid Signaling: Mechanism for Bariatric Surgery, Cure for NASH?
    Dig Dis. 2015;33:440-6.
    PubMed     Text format     Abstract available


  75. TRAUNER M, Halilbasic E, Claudel T, Steinacher D, et al
    Potential of nor -Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders.
    Dig Dis. 2015;33:433-9.
    PubMed     Text format     Abstract available


  76. SANYAL AJ
    Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease.
    Dig Dis. 2015;33:426-32.
    PubMed     Text format     Abstract available


  77. MASYUK TV, Masyuk AI, LaRusso NF
    TGR5 in the Cholangiociliopathies.
    Dig Dis. 2015;33:420-5.
    PubMed     Text format     Abstract available


  78. ZIMMER V, Liebe R, Lammert F
    Nuclear receptor variants in liver disease.
    Dig Dis. 2015;33:415-9.
    PubMed     Text format     Abstract available


  79. KRONES E, Wagner M, Eller K, Rosenkranz AR, et al
    Bile Acid-induced cholemic nephropathy.
    Dig Dis. 2015;33:367-75.
    PubMed     Text format     Abstract available


  80. ABU-HAYYEH S, Williamson C
    Progesterone metabolites as farnesoid X receptor inhibitors.
    Dig Dis. 2015;33:300-6.
    PubMed     Text format     Abstract available


  81. VAN BUUREN HR, Lammers WJ, Harms MH, Hansen BE, et al
    Surrogate Endpoints for Optimal Therapeutic Response to UDCA in Primary Biliary Cholangitis.
    Dig Dis. 2015;33 Suppl 2:118-24.
    PubMed     Text format     Abstract available


  82. POUPON R
    Non-Invasive Assessment of Liver Fibrosis Progression and Prognosis in Primary Biliary Cholangitis.
    Dig Dis. 2015;33 Suppl 2:115-7.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: